This site uses cookies to store information on your computer. Learn more x

Consensus Figures

A number of international financial analysts cover DSM. The most recent consensus figures – provided by Vara Research – are detailed below. The figures are based on the estimates given by the banks that were approached by Vara Research.

Analysts' consensus Q1 2019 and FY 2019 as at 15 April 2019

  Q1 2018 FY 2018 Q1 2019 E* FY 2019 E*
Sales (continuing)        
Number of Estimates     16 17
Highest     2,486 9,564
Consensus 2,435 9,267 2,297 9,331
Median     2,273 9,343
Lowest     2,229 9,010
adj. EBITDA (continuing)        
Number of Estimates     16 17
Highest     409 1,727
Consensus 538 1,822 397 1,665
Median     394 1,660
Lowest     383 1,629
of which estimated adj. EBITDA from"Temporary Vitamin Effect"        
Number of Estimates     11 12
Highest     0 0
Consensus 165 290 0 0
Median     0 0
Lowest     0 0
Underlying business,  adj. EBITDA        
Number of Estimates     16 17
Highest     409 1,727
Consensus 373 1,532 397 1,665
Median     394 1,660
Lowest     383 1,629
adj. EBIT (continuing)        
Number of Estimates     13 16
Highest     280 1,189
Consensus 423 1,345 268 1,140
Median     265 1,139
Lowest     259 1,091
Nutrition, Sales        
Number of Estimates     15 15
Highest 1,650 6,137 1,699 6,385
Consensus     1,514 6,148
Median     1,495 6,136
Lowest     1,448 5,906
Nutrition, adj. EBITDA        
Number of Estimates     15 15
Highest 442 1,407 311 1,289
Consensus     298 1,240
Median     299 1,240
Lowest     285 1,197
of which adj. EBITDA from"Temporary Vitamin Effect"        
Number of Estimates     11 11
Highest 165 290 0 0
Consensus     0 0
Median     0 0
Lowest     0 0
Nutrition underlying,  adj. EBITDA        
Number of Estimates     15 15
Highest 277 1,117 311 1,289
Consensus     298 1,240
Median     299 1,240
Lowest     285 1,197
Nutrition, adj. EBIT        
Number of Estimates     12 13
Highest 370 1,111 233 969
Consensus     219 915
Median     219 915
Lowest     210 863
Materials, Sales        
Number of Estimates     15 15
Highest 738 2,913 766 3,042
Consensus     735 2,960
Median     738 2,965
Lowest     701 2,876
Materials, adj. EBITDA        
Number of Estimates     15 15
Highest 126 512 128 545
Consensus     123 518
Median     125 516
Lowest     117 501
Materials, adj. EBIT        
Number of Estimates     12 13
Highest 95 383 96 428
Consensus     89 380
Median     90 379
Lowest     79 331
Innovation Center, Sales        
Number of Estimates     15 15
Highest 36 172 47 191
Consensus     40 181
Median     39 180
Lowest     36 172
Innovation Center, adj. EBITDA        
Number of Estimates     15 15
Highest -1 8 5 32
Consensus     2 14
Median     3 13
Lowest     -1 5
Innovation Center, adj. EBIT        
Number of Estimates     12 13
Highest -6 -14 -2 -9
Consensus     -4 -14
Median     -4 -11
Lowest     -9 -32
Corporate Activities, Sales        
Number of Estimates     15 15
Highest 11 45 18 70
Consensus     12 48
Median     11 46
Lowest     10 45
Corporate Activities, adj. EBITDA        
Number of Estimates     15 15
Highest -29 -105 -25 -95
Consensus     -27 -106
Median     -27 -106
Lowest     -29 -110
Corporate Activities, adj. EBIT        
Number of Estimates     12 13
Highest -36 -135 -32 -133
Consensus     -35 -138
Median     -35 -138
Lowest     -37 -145
Profit for the period, before exceptional items - Cont. Ops.        
Number of Estimates     12 14
Highest 337 1,034 217 923
Consensus     204 863
Median     205 865
Lowest     191 813
Net EPS before exceptional items - Cont. Ops.        
Number of Estimates     12 14
Highest 1.91 5.84 1.25 5.30
Consensus     1.16 5.00
Median     1.16 5.00
Lowest   0.72 1.08 4.71

* Analysts were asked by Vara Research to include the estimated IFRS16 effect in the DSM consensus poll for 2019 Q1 and FY 2019.
 

Related links

Disclaimer
Consensus earnings estimates are based on earnings projections made by securities analysts who cover DSM. Any opinions, forecasts, estimates, projections or predictions regarding DSM’s performance made by the analysts (and, therefore, the Consensus estimate numbers) are theirs alone and do not represent the opinions, forecasts, estimates, projections or predictions of DSM or its management. DSM does not by providing these estimates imply its endorsement of or concurrence with such information, conclusions or recommendations. DSM assumes no liability for the accuracy of such estimates and undertakes no obligation to update or revise such estimates.